Answers are grounded in this paper and cite their sources.
Osteosarcoma chemoresistance remains a fundamental barrier to durable disease control. Survival following conventional chemotherapy with agents such as doxorubicin and cisplatin may require osteosarcoma cells to adapt to oxidative and electrophilic stress. This review evaluates how adaptive redox remodeling, primarily coordinated through the NRF2 regulatory hub, can promote stress tolerance while creating potential therapeutic vulnerabilities. Osteosarcoma-specific evidence linking SLC7A11-mediated cystine uptake, glutathione metabolism, and GPX4-regulated lipid peroxide defense to ferroptosis-related vulnerabilities is synthesized. Direct functional evidence from chemotherapy-resistant osteosarcoma models is distinguished from osteosarcoma-specific findings obtained in other experimental contexts and mechanistic extrapolations from other cancer types, highlighting that ferroptotic susceptibility is context-dependent and dynamically regulated rather than an established feature of all resistant tumors. Because disruption of lipid peroxide defenses can trigger secondary compensatory responses, therapeutic strategies cannot rely on indiscriminate reactive oxygen species (ROS) generation alone. Exploiting potential vulnerabilities will require a precision-medicine framework supported by functionally validated predictive biomarkers, physiologically relevant models, and tumor-selective delivery platforms.
No takes yet. Share an insight, caveat, or question.
Pant et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: